As can be seen in Figure 1B, the implementation of the blood–tumor barrier (BTB) opening procedure with the B1R/B2R agonist combo before DOX administration resulted in higher fluorescent DOX distribution at primary sites and perivascular satellite tumor nodules. The gene discussed is BDKRB2; the disease is neoplasm.